We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First person profile: Patricia M. LoRusso, DO: This researcher and clinician has conducted work in early‐phase trials that has led to the approval of several anticancer agents, all while keeping her focus on the patients she says make these trials possible
- Authors
Nierengarten, Mary Beth
- Abstract
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, researcher and clinician Patricia M. LoRusso, DO, keeps her focus on patients as she conducts work in early‐phase trials that has led to the approval of several anticancer agents. In addition, the Food and Drug Administration has approved a niraparib and abiraterone acetate combination treatment for advanced prostate cancer, and researchers have identified two new subtypes of human papillomavirus‐related head and neck cancers.
- Subjects
UNITED States. Food &; Drug Administration; RESEARCH personnel; ANTINEOPLASTIC agents; HEAD &; neck cancer; ABIRATERONE acetate; POLICY analysis
- Publication
Cancer (0008543X), 2023, Vol 129, Issue 24, p3840
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.35121